Medtronic’s (MDT) Valiant Captivia is a thoracic stent graft delivery system for aortic therapies. It helps enable controlled stent deployment and placement and a three-step delivery process. The device has been used to treat more than 85,000 patients worldwide. The device first received CE mark approval in Europe in 2009 and FDA approval in the US in 2011.
On September 20, 2016, Medtronic posted its new safety and efficacy data for its Valiant Captivia Thoracic Stent Graft System. The data affirmed the device’s safety and efficacy for three years in Type B aortic dissection patients treated with the device. The IDE (investigational device exemption) trial involved 50 patients. It was conducted at 16 sites in the US. Around 90% of patients were found to be free from dissection-related mortality risk and around 79.4% of patients were found to be free from all-cause mortality risks.
St. Jude Medical (STJ), Boston Scientific (BSX), and Edwards Lifesciences (EW) are Medtronic’s major competitors that offer aortic dissection treatment therapies. Investors can invest in the iShares Russell 1000 ETF (IWB) to gain exposure to Medtronic, which accounts for ~0.57% of IWB’s total holdings.